See inside every stock. Pro
S&P 5007,624▼ 0.52%Nasdaq25,955▼ 0.21%Dow Jones52,215▼ 1.23%Nasdaq 10028,958▼ 0.00%VIX19.45▲ 2.21%US Dollar101.75▲ 0.14%Gold spot3,994▼ 0.75%WTI103.27▲ 3.82%
London Exchange · UK · Updated after 23 Oct 2026 close

Supernus Pharmaceuticals, Inc.

0LB2 · London Exchange · prices in USD
USD 40.56▼ -0.89 (2.15%)
Research reportHistorical data

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a pharmaceutical company that develops and commercialises medicines for central nervous system conditions. Its products treat epilepsy and attention deficit hyperactivity disorder, and it also markets treatments for migraine and movement disorders. The company serves patients and prescribers through neurologists, psychiatrists and other specialists, and it carries out its own research and development alongside its commercial operations. Supernus Pharmaceuticals is based in Rockville, Maryland, in the United States.

On this site Supernus Pharmaceuticals, Inc. appears as a stock on the London Exchange (UK), code 0LB2, with prices in US dollars (USD). Dividend data for this stock is not available yet. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

26/ 100
Market X-Ray · price-based
Weak price profile
Ranks #3219 of 3787 on the London Exchange · confidence Medium
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendWeak
25/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-15.0%
From 52-week high-27.9%
MomentumWeak
21/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-14.9%
6-month return-17.2%
Stability (higher is calmer)Weak
43/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)39.2%
Worst drawdown, 1 year (smaller is calmer)-32.2%
LiquidityWeak
10/100
Thinly traded: prices can jump and exits can be hard.
See the numbers →
Avg daily value traded0.01M USD
Zero-volume days11.7%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
Price trend
Below its 200-day average
Versus its 50- and 200-day averages
52-week range
37.96 – 59.74
Price is 12% of the way up
Returns
−14.9% 3m · – 1y
Price returns, dividends not included
RSI (14)
44
Neutral zone

Price chart

52-wk range 37.96 – 59.74 Daily closes, split-adjusted

Signals

50-day average43.63
200-day average47.73
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)1.27

Technical summary

Daily
Strongly bearish
0 bullish · 4 neutral · 11 bearish
Weekly
Strongly bearish
0 bullish · 1 neutral · 6 bearish
Monthly
Strongly bearish
0 bullish · 0 neutral · 1 bearish
Moving averages (daily)
SMA 1041.00Bearish
EMA 1041.00Bearish
SMA 2042.03Bearish
EMA 2041.64Bearish
SMA 5043.63Bearish
EMA 5043.18Bearish
SMA 10044.99Bearish
EMA 10044.76Bearish
SMA 20047.73Bearish
EMA 200–n/a
Oscillators (daily)
RSI (14)44.00Neutral
MACD (12, 26)-0.86Bearish
Momentum (12)-5.99Bearish
Stochastic %K (14)46.94Neutral
Williams %R (14)-53.06Neutral
CCI (20)-58.70Neutral
Pivot points (classic, last session)
S3
38.51
S2
39.47
S1
40.02
Pivot
40.98
R1
41.53
R2
42.49
R3
43.04
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Prices are end-of-day closes in USD. Educational only, not financial advice.